Jong-Mu Sun

Jong-Mu Sun

Auto-generated profile, based on publicly available information

Jong-Mu Sun

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in The Lancet
Verified
Journal Article
Closed access
JSJong-Mu Sun
Jong-Mu Sun
LSLin Shen
Lin Shen
MSManish A Shah
Manish A Shah
PEPeter Enzinger
Peter Enzinger
AAAntoine Adenis
Antoine Adenis
KKKen Kato
Ken Kato

1 January 2018 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
SPSong Ee Park
Song Ee Park
SLSe Hoon Lee
Se Hoon Lee
JAJin Seok Ahn
Jin Seok Ahn
MAMyung-Ju Ahn
Myung-Ju Ahn
KPKeunchil Park
Keunchil Park
JSJong-Mu Sun
Jong-Mu Sun

1 January 2016 in European Journal of Cancer
Verified
Journal Article
Closed access
SLSung Hee Lim
Sung Hee Lim
MHM. Hong
M. Hong
SAS. Ahn
S. Ahn
YCY.-L. Choi
Y.-L. Choi
KKK.-M. Kim
K.-M. Kim
JSJ.-M. Sun
J.-M. Sun

15 April 2019 in Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
YKYoujin Kim
Youjin Kim
SLSe-Hoon Lee
Se-Hoon Lee
JAJin Seok Ahn
Jin Seok Ahn
MAMyung-Ju Ahn
Myung-Ju Ahn
KPKeunchil Park
Keunchil Park
JSJong-Mu Sun
Jong-Mu Sun
We tried to evaluate whether there are any specific features in treatment outcomes of firstline afatinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), compared with gefitinib or erlotinib. We analyzed patients treated with first-line afatinib, gefitinib, or erlotinib for advanced EGFR-mutant NSCLC at Samsung Medical Center between 2014 and 2016. In total, 467 patients received first-line afatinib (n=165), gefitinib (n=230), or erlotinib (n=72). Afatinib was used more often in patients with tumors harboring deletion in exon 19 (Del19), whereas the gefitinib group had more elderly, females, and never smokers. The median progression-free survival (PFS) time for afatinib, gefitinib, and erlotinib was 19.1 months, 13.7 months, and 14.0 months, respectively (p=0.001). The superior PFS of afatinib was more remarkable in subgroups of Del19 or uncommon EGFR mutations. Overall toxicity profiles of the three drugs were comparable, though more grade 3 or 4 toxicities were detected in afatinib (7.3%) compared with gefitinib (2.6%) or erlotinib (1.8%). The common grade 3 or 4 toxicities of afatinib included diarrhea (3.0%), paronychia (2.4%), and skin rash (1.8%). Dose modification was more frequently required in patients treated with afatinib (112/165, 68%), compared with gefitinib (5/230, 2%) and erlotinib (4/72, 6%). Interestingly, however, dose reduction in the afatinib group did not impair its efficacy in terms of PFS (dose reduction vs. no reduction group, 23.5 months vs. 12.4 months). First-line afatinib showed satisfactory efficacy data and manageable toxicity profiles.

23 March 2022 in Cancer
Verified
Journal Article
Closed access
SPSehhoon Park
Sehhoon Park
DODongryul Oh
Dongryul Oh
YCYoon‐La Choi
Yoon‐La Choi
SCSang Ah Chi
Sang Ah Chi
KKKyunga Kim
Kyunga Kim
JSJong‐Mu Sun
Jong‐Mu Sun

12 February 2022 in ESMO Open
Verified
Journal Article
Open access
SPS. Park
S. Park
JSJ.-M. Sun
J.-M. Sun
YCY.-L. Choi
Y.-L. Choi
DOD. Oh
D. Oh
HKH.K. Kim
H.K. Kim
YSY.M. Shim
Y.M. Shim
We evaluated the efficacy of adjuvant durvalumab after neoadjuvant concurrent chemoradiotherapy (CCRT) in patients with esophageal squamous cell carcinoma (ESCC). This randomized, double-blind, phase II study included patients with ESCC who underwent curative surgery after neoadjuvant CCRT. Patients were randomized to receive either durvalumab (20 mg/kg/i.v. every 4 weeks for 12 months) or placebo in a 1:1 ratio and were stratified by age and pathologic tumor stage. The primary endpoint was disease-free survival (DFS). Between March 2016 and June 2018, 86 patients were randomized to the durvalumab (n = 45) or placebo (n = 41) arm. The median follow-up duration was 38.7 months. There was no difference in DFS [hazard ratio (HR) 1.18, 95% confidence interval (CI) 0.62-2.27, P = 0.61] or overall survival (HR 1.08, 95% CI 0.52-2.24, P = 0.85) between the two arms. Subgroup analysis was performed for patients for whom the post-CCRT programmed death-ligand 1 (PD-L1) expression profile could be assessed (n = 54). In the PD-L1-positive group, based on tumor proportion score ≥1%, durvalumab was associated with longer overall survival compared with the placebo (36-month survival rate: 94% versus 64%; HR 0.42, 95% CI 0.10-1.76), while in the PD-L1-negative group, it was associated with shorter overall survival (42% versus 55%; HR 1.53, 95% CI 0.48-4.83), showing the tendency of interaction between post-CCRT PD-L1 status and adjuvant durvalumab therapy for overall survival (interaction P = 0.18). We failed to demonstrate that adjuvant durvalumab improved survival after neoadjuvant CCRT in patients with ESCC. However, post-CCRT PD-L1 expression could predict the survival of patients who receive adjuvant durvalumab after neoadjuvant CCRT, which needs to be validated.